US FDA Promises Shorter, Quicker Drug GMP Warning Letters
This article was originally published in SRA
The US Food and Drug Administration is writing shorter drug GMP warning letters in an effort to issue them more quickly.
You may also be interested in...
House passes bill reauthorizing FDA user fee programs via voice vote and makes many other policy changes, but in the process touts the bill's potential to push drug prices lower.
Ashley's many years in the Department of Justice’s Office of International Affairs should be a plus for agency's globalization efforts.
FDA has published a warning letter that not only provides detailed guidance for Teva’s ongoing remediation of sterility assurance failures at a plant in Godollo, Hungary, but also suggests a game plan for any manufacturer of sterile drug products that’s seeing signs of issues with aseptic operations.